Florida Sues Pfizer, CEO Over Alleged Misleading COVID Vaccine Marketing

Florida has moved its scrutiny of COVID-19 vaccines into a profit-focused consumer-protection case, suing Pfizer and CEO Albert Bourla less than two years after a statewide grand jury investigating vaccine manufacturers found no evidence of criminal activity.

Attorney General James Uthmeier filed the 49-page civil complaint on October 1 in St. Lucie County Circuit Court, accusing Pfizer and Bourla of violating the Florida Deceptive and Unfair Trade Practices Act through allegedly misleading vaccine marketing and unfair commercial practices.

The state is seeking an injunction, disgorgement of profits, and civil penalties. Florida law allows penalties of up to $10,000 for each willful violation and up to $15,000 for qualifying violations involving senior citizens or people with disabilities.

PTX Metals Inc. — sponsored Sponsored · PTX Metals Inc.

Florida alleges Pfizer generated more than $80 billion from its COVID-19 vaccine before substantially raising its price.

The company reported $36.78 billion in Comirnaty revenue in 2021, $37.81 billion in 2022, and $11.22 billion in 2023. Combined, those three years produced approximately $85.81 billion in reported revenue.

The complaint alleges Pfizer later increased the vaccine’s price from roughly $30 per dose to between $110 and $130 in 2023. Florida also accuses the company of using unfair tactics to protect its market position.

Florida has not said it is seeking the entire $80 billion-plus in vaccine sales.

The state separately alleges Pfizer misrepresented or failed to adequately disclose certain safety risks and promoted vaccination as a way to protect others despite not initially testing whether the vaccine prevented transmission.

“The representations made by Pfizer about its COVID-19 vaccine have been accurate and science-based, and the Company stands behind the safety and efficacy of its vaccine,” the company said, adding that it believes Florida’s claims have no merit.

The civil case follows a Florida statewide grand jury investigation requested by Gov. Ron DeSantis in 2022. Its final report, released in January 2025, produced no indictments and said it found no evidence of criminal activity by vaccine manufacturers, although it criticized aspects of vaccine development, safety monitoring, and pharmaceutical regulation.

Florida’s action also joins existing state litigation rather than opening a new legal front nationally. Texas sued Pfizer in 2023, while Kansas brought its own consumer-protection case in 2024.

Information for this briefing was found via the sources and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

One Response

Leave a Reply

Video Articles

Everybody Should Own Gold | George Bee – U.S. Gold Corp.

A $40M Company Created $2B in Mining Value | John-Mark Staude – Riverside Resources

The Debt Crisis Is Turning Gold Into Money | Shawn Khunkhun – Contango Silver and Gold

Recommended

Northmin Wins Competitive Bid for Historic Keel Zinc-Silver-Lead Deposit in Ireland

Brixton Hits 348 g/t Silver Over 23.5 Metres as Langis Shaft 6 Southeast Zone Extends South

Related News

Vivek Ramaswamy’s Roivant Sells Drugmaker Televant For $7.1 Billion After Acquiring It For $45 Million From Pfizer

On Monday, Swiss healthcare firm Roche made a significant announcement, revealing its acquisition of Telavant...

Thursday, October 26, 2023, 11:28:00 AM

Former Pfizer Employee Charged by SEC for Insider Trading

Former Pfizer Inc. (NYSE: PFE) employee Amit Dagar and his close friend and business partner,...

Friday, June 30, 2023, 10:58:00 AM

Pfizer Stock Unfazed By $9 Billion Cut In Revenue Projections

On the first day of trading following the Pfizer’s (NYSE: PFE) announcement of weaker-than-expected sales...

Monday, October 16, 2023, 03:51:00 PM

Pfizer To Acquire Clinical-Stage Biotech Firm Arena Therapeutics For US$6.7 Billion

Pfizer Inc. (NYSE: PFE) announced on Monday the definitive agreement to acquire clinical stage biopharmaceutical...

Friday, December 17, 2021, 10:58:00 AM

Well Health, Bombardier To Be Added To S&P/TSX Composite Index

The latest changes for the S&P/TSX Composite Index, assembled by S&P Down Jones Indices, were...

Sunday, September 5, 2021, 12:09:00 PM